Clinical Trial Search

Primary: Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants — 19.2; -37.2…

Primary: Percent Change From Baseline to Week 8 in Serum Triglyceride (TG) — -57.33; -11.85 percent change from Baseline — p=<0.001

Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -7.0; -26.6; 9.7 Percent change from baseline — p=<0.0001

Primary: Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG) — -47.32; -32.95; -27.30 Percent Change — p=0.0063

Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL

Primary: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG) — -17.2; -66.0; -70.2; -74.2 percentage change — p=< 0.0001

Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -5.6; -17.5; 5.9 Percent change from baseline — p=<0.0001

Primary: Percent Change From Baseline in Fasting TG at Month 6 — -7.77; -57.05; -60.92 Percent Change — p=<0.0001

Primary: Percent Change in Fasting TG From Baseline to Week 12 — -58.89; -22.94 Percent change — p=<0.0001

Primary: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 — -56.00; -7.97 Percent of Change — p=<0.0001

Primary: Absolute Change From Baseline to Month 3 in Fasting Triglycerides (TG) — -550.00 mg/dL

Primary: Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) — -17.9; -25.0; -26.6; -2.1 Percent Change — p=<0.0001

Primary: Percent Change in Fasting Triglycerides From Baseline to 12 Weeks — 45.6; 3.7; -13.9 percent change — p=0.0538

Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid

Primary: Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point — 6; -23; -56; -60 percent change — p=0.0042

Primary: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 — -0.9; -71.2 percent change — p=<0.0001

Primary: Change in Triglyceride Level — -52; -16 mg/dL

Primary: Percentage Change in Serum Triglyceride Levels From Baseline to Week 12 of Study Treatment — -39.1; -14.6 Percent change (%) — p=<0.01

Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 8; 10; 8; 11 Participants

Primary: Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period — -40.2; -33.7 percent change…

Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants

Primary: Difference Between Treatments in Liquid Meal Tolerance Test (LMTT) Matsuda Insulin Sensitivity Index (MISI). — 3.2; 3.3 Index value — p=0.959

Primary: Pre- and Post-Intervention Triglyceride Levels — 231; 209; 201; 140 mg/dL

Primary: Percent Change in LDL-C From Baseline to Week 12 — -25.25; -3.46 Percent Change — p=0.001

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 106; 110; 109 participants

Primary: Fasting Serum Triglycerides — -4.26; -25.94; -25.46; -30.86 Percent change from baseline — p=0.005

Primary: Change in Triglycerides From Baseline to 16 Weeks — -54.13 mg/dL

Primary: Serum Non-HDL Cholesterol — -3.86; -6.91; -0.91 Percent change from baseline — p=<0.05

Primary: Change in Fasting Serum Triglyceride (at 12 Weeks) — -0.44; -20.27 percent change — p=0.517

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001